Please assess the completion status of the following clinical trial:

Trial Title: PharmacofMRI of Anxiolytic Medications (Pregabalin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, or female (not pregnant or intending to become pregnant during the study)~* Between the ages of 18-30.~* In good general health.~* No specific contraindications to the drug being administered~Exclusion Criteria:~* Subjects with a history of DSM-IV depressive disorder, psychotic disorder, anxiety disorder~* Subjects who meet criteria for substance abuse or dependence within the last 6 months~* Subjects with an positive urine screen for illicit drugs having clinically significant abnormal laboratory, ECG or physical examination findings not resolved by the baseline visit~* Patients who have taken psychotropic drugs or antidepressants (including monoamine oxidase inhibitors, MAOI's) within the last year~* Subjects who are left-handed.~* Subjects suffering suffers from claustrophobia, or phobia for injections or blood~* Magnetic Resonance Imaging related exclusion criteria: cardiac pacemaker, metal fragments in eyes/skin/body (shrapnel), subjects who have ever been a metal worker/welder; history of eye surgery/eyes washed out because of metal, aortic/aneurysm clips, prosthesis, by-pass surgery/coronary artery clips, hearing aid, heart valve replacement, subjects who are in the first trimester of pregnancy, subjects with an I.U.D. (birth control device), a shunt (ventricular or spinal), electrodes, metal plates/pins/screws/wires, or neuro/bio-stimulators (TENS unit).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Pregabalin 50 mg (Type: ACTIVE_COMPARATOR): Pregabalin oral tablets (50 mg)
- Pregabalin 200 mg (Type: ACTIVE_COMPARATOR): Pregabalin oral tablets (200 mg)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).